SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/ECB92042E83C86DF0AD2AB6E5A40782C5F8A62F51960E69E392BFEDDB550874B35F28F9EC3A530558702411311523FD5>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/ECB92042E83C86DF0AD2AB6E5A40782C5F8A62F51960E69E392BFEDDB550874B35F28F9EC3A530558702411311523FD5
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/ECB92042E83C86DF0AD2AB6E5A40782C5F8A62F51960E69E392BFEDDB550874B35F28F9EC3A530558702411311523FD5
http://www.w3.org/2000/01/rdf-schema#comment
"Results show that Janus kinase 2 inhibitors may enhance the cytotoxic effect of ABL kinase inhibitor imatinib against residual chronic myeloid leukemia (CML) cells."
xsd:string
http://purl.uniprot.org/uniprot/#_7E7B1CCB550EB6D11CEF6FBD8B973E366608BBCDBF3CBA739D5D7C41C55DA1480974E5D133257CF5D0035B1F0F3707A5
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/ECB92042E83C86DF0AD2AB6E5A40782C5F8A62F51960E69E392BFEDDB550874B35F28F9EC3A530558702411311523FD5
http://purl.uniprot.org/uniprot/Q59FK4
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/ECB92042E83C86DF0AD2AB6E5A40782C5F8A62F51960E69E392BFEDDB550874B35F28F9EC3A530558702411311523FD5
http://purl.uniprot.org/uniprot/#_Q59FK4-mappedCitation-24775308
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/ECB92042E83C86DF0AD2AB6E5A40782C5F8A62F51960E69E392BFEDDB550874B35F28F9EC3A530558702411311523FD5